Scarica l'app Stockscreener
0.152
4.40%
-0.007
Pre-mercato:
.18
0.028
+18.42%
Precedente Chiudi:
$0.159
Aprire:
$0.1537
Volume 24 ore:
3.95M
Relative Volume:
0.87
Capitalizzazione di mercato:
$2.94M
Reddito:
-
Utile/perdita netta:
$-25.09M
Rapporto P/E:
-0.0293
EPS:
-5.1824
Flusso di cassa netto:
$-18.40M
1 W Prestazione:
-10.22%
1M Prestazione:
-18.10%
6M Prestazione:
-87.84%
1 anno Prestazione:
-95.91%
Intervallo 1D:
$0.1454
$0.1567
Intervallo di 1 settimana:
$0.1201
$0.1783
Portata 52W:
$0.1201
$19.20
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Nome
Calidi Biotherapeutics Inc
Settore
Industria
Telefono
(858) 794-9600
Indirizzo
4475 Executive Drive, Suite 200, San Diego
Compare CLDI vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.152 | 3.13M | 0 | -25.09M | -18.40M | -5.1824 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-22 | Iniziato | H.C. Wainwright | Buy |
| 2023-10-09 | Iniziato | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Borsa (CLDI) Ultime notizie
CLDI Q4 2025 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesAdjusted Earnings Analysis - The League of Women Voters of Texas
CLDI Q4 2025 Earnings: Narrower Loss Signals Progress in Clinical PipelineProfit Inflection Point - newsline.com
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9 - ACCESS Newswire
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026 - GlobeNewswire
Calidi Biotherapeutics (CLDI) Edges Lower, Testing Key Support at $0.16Regression Channel - newsline.com
CLDI Q4 2025 Earnings: Significant EPS Beat Highlights Progress in Oncolytic Virus Therapy DevelopmentFull Year Guidance - newsline.com
Calidi Biotherapeutics (CLDI) Hovers Near Key Support Amid Continued Selling PressureShakeout Pattern - newsline.com
Calidi Biotherapeutics, Inc. Files Form 8-K Disclosing Amended and Restated Warrant Agreement – Key Details and XBRL Data - Minichart
Calidi Biotherapeutics Amends Warrant in Private Placement - TipRanks
Calidi Biotherapeutics Amends Warrant for 17.4M Shares at $0.23; Stockholder OK Required - TradingView
Calidi (NYSE: CLDI) extends vesting and adjusts major warrant terms - Stock Titan
CLDI Q4 2025 Earnings: Narrower-Than-Expected Loss as Clinical Progress ContinuesROIC Trend Report - newsline.com
Number of shareholders of Calidi Biotherapeutics, Inc. – AMEX:CLDI - TradingView
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting - Weekly Voice
Tumor-targeting virotherapy from Calidi to appear at 2026 ASCO - Stock Titan
Calidi Biotherapeutics (CLDI) Declines Slightly, Approaching Key Support at $0.16Put Flow Alert - newsline.com
Calidi Biotherapeutics Q4 2025 Earnings: Narrowed Loss Surprises, Stock DeclinesEarnings Season Review - newsline.com
Calidi Biotherapeutics Q4 2025 Earnings: Narrowed Loss Per Share Exceeds Expectations Despite Stock Decline - Newser
Calidi Biotherapeutics Provides Required NYSE American Disclosure - The Manila Times
Calidi Biotherapeutics discloses NYSE-required audit note on going concern status in 2025 financial report. - Pluang
Calidi Biotherapeutics, Inc. Issues Financial Statement Audit Report Highlighting Going Concern Assumption - Quiver Quantitative
Biotech Calidi’s 2025 audit report includes 'going concern' note - Stock Titan
Armistice Capital (CLDI) reports 1.11M shares, 9.99% ownership - Stock Titan
Calidi Highlights Q1 Results and RedTail Platform Progress - TipRanks
Calidi Biotherapeutics 1Q 2026: Net loss $4.42M, EPS $(0.43) — 10-Q Summary - TradingView
Calidi Biotherapeutics (CLDI) Q1 2026 loss, cash runway and warrant overhang detailed - Stock Titan
Calidi Biotherapeutics (NYSE: CLDI) Q1 2026 loss narrows as cash rises - Stock Titan
Biotech Calidi cuts costs, taps AI partner for CLD-401 IND - Stock Titan
Press Release: Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights - Moomoo
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights - GlobeNewswire
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston - GlobeNewswire
Calidi virotherapy delivers genetic meds inside tumors, ASGCT talk set - Stock Titan
TradingKey - TradingKey
How Calidi (CLDI) maintains its competitive edge | Q4 2025: Better Than ExpectedFree Cash Margin - Newser
Calidi Biotherapeutics, Inc. Files Form 8-K for Material Definitive Agreement and Common Stock Purchase Warrants – SEC Filing May 6, 2026 - Minichart
Calidi Biotherapeutics Issues Private Placement Warrant Financing - TipRanks
Calidi Biotherapeutics Issues Warrant for 17.4M Shares, Linked to Up to $4M Stock Buys at $0.23 - TradingView
Calidi Biotherapeutics (CLDI) grants 17.4M-share warrant linked to $4M equity - Stock Titan
Calidi Biotherapeutics announces underwritten public offering - Investing.com
CLDI Stock Price, Quote & Chart | CALIDI BIOTHERAPEUTICS INC (NYSEARCA:CLDI) - ChartMill
DEFA14A: Others - Moomoo
Calidi Biotherapeutics (CLDI) sets vote on reverse split and larger equity plan - Stock Titan
Calidi Biotherapeutics announces strategic partnership with Transferai - marketscreener.com
Calidi partners with TransferAI for CLD-401 regulatory filing By Investing.com - Investing.com South Africa
Calidi partners with TransferAI for CLD-401 regulatory filing - Investing.com
Calidi Biotherapeutics Announces Strategic Partnership With Transferai - TradingView
Calidi turns to AI software as it pushes CLD-401 toward filing - Stock Titan
Calidi (CLDI) Stock: What Is Driving the Price | Q4 2025: EPS Tops ViewsTax Rate Impact - newsline.com
Calidi (CLDI) Stock: Breakout Potential Analysis | Q4 2025: Better Than ExpectedVerified Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai
CLDI (Calidi Biotherapeutics Inc.) posts 73.6% positive Q4 2025 EPS surprise, shares edge slightly lower in today’s trading.Revenue Diversification - Cổng thông tin điện tử tỉnh Lào Cai
Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 - marketscreener.com
Calidi Biotherapeutics Inc Azioni (CLDI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.60%
0.94%
Capitalizzazione:
|
Volume (24 ore):